Applications
- Higher neutralization titer doesn’t always mean better protection: A study on the live-attenuated influenza vaccine shows no correlation between increased antibody levels and improved immunity.
- Neutralization titer increase does not guarantee influenza protection: Despite a tenfold rise in titer, the rate of influenza positivity remained unchanged.
- Functional assays are essential: Measuring antibody levels alone isn’t enough; functional assays are needed to assess true immune protection.
- Comparative Functional Profiling of CD20 mAbs: Rituximab, Ofatumumab, and Obinutuzumab exhibit distinct profiles in C1q binding, ADCD, and CDC activities, enabling developers to evaluate complement-related mechanisms across therapeutic antibodies targeting the same antigen.
- Ofatumumab Shows Highest Complement Activation Potential: Among the three CD20 mAbs, Ofatumumab demonstrates the strongest C1q binding and ADCD response, suggesting enhanced CDC potency and potential for superior direct complement-mediated cytotoxicity.
- Obinutuzumab’s Fc Engineering Impacts Complement Function: Obinutuzumab, an afucosylated Type II mAb, shows significantly reduced C1q binding and CDC despite strong ADCP, emphasizing the importance of Fc design choices on effector function profiles.
About Us
SeromYx partners with biopharma, biotech, and government teams to support the development of antibody therapeutics and vaccines through expert analysis, collaboration, and scientific insight.
Partnered across
14
Countries
Trusted and Registered
Supplier: Scientist.com
Partner of the
Good Clinical
Laboratory Practice
